<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="Publisher" Owner="NLM">        <PMID Version="1">30242581</PMID>        <DateRevised>            <Year>2018</Year>            <Month>09</Month>            <Day>22</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">1573-7217</ISSN>                <JournalIssue CitedMedium="Internet">                    <PubDate>                        <Year>2018</Year>                        <Month>Sep</Month>                        <Day>21</Day>                    </PubDate>                </JournalIssue>                <Title>Breast cancer research and treatment</Title>                <ISOAbbreviation>Breast Cancer Res. Treat.</ISOAbbreviation>            </Journal>            <ArticleTitle>Rate of radial scars by core biopsy and upgrading to malignancy or high-risk lesions before and after introduction of digital breast tomosynthesis.</ArticleTitle>            <ELocationID EIdType="doi" ValidYN="Y">10.1007/s10549-018-4973-x</ELocationID>            <Abstract>                <AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">Radial scars (RS) commonly present mammographically as architectural distortions, but these lesions may be associated with non-invasive and invasive breast cancer. Digital breast tomosynthesis (DBT) has resulted in higher detection rates of architectural distortion particularly in patients with dense breast tissue. We hypothesized that rates of clinically relevant lesions confirmed surgically would be lower in patients who received DBT imaging compared with those who received standard digital breast imaging.</AbstractText>                <AbstractText Label="METHODS" NlmCategory="METHODS">We performed a retrospective review of 223 patients diagnosed with pure RS by core biopsy and surgical excision before and after DBT was introduced. The rate of upgrading to malignancy or high-risk lesion was evaluated. Demographics, biopsy type, and histologic data were analyzed. Univariable logistic regression analysis was used to identify variables that may be associated with upgrading.</AbstractText>                <AbstractText Label="RESULTS" NlmCategory="RESULTS">The rate of identifying RS increased from 0.04-.13% (P &lt; 0.0001) with DBT imaging. The upgrade rate on surgical specimen to invasive or non-invasive cancer was similar before and after DBT; 6% versus 3%, as were findings of a high-risk lesion; 12% versus 22%. No predictive factors were identified for patients upgraded to malignant neoplasms or high-risk lesions.</AbstractText>                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The likelihood of identifying RS has increased with DBT imaging, but rates of upgrading to a malignant neoplasm or high-risk lesion were similar to those before DBT. Although the rate of upgrading to malignancy after DBT was low, an excisional biopsy should be considered as 22% of patients were upgraded to high-risk lesions. These patients are candidates for chemoprevention and/or high-risk surveillance.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Phantana-Angkool</LastName>                    <ForeName>April</ForeName>                    <Initials>A</Initials>                    <AffiliationInfo>                        <Affiliation>Division of Surgical Oncology, Department of Surgery, Levine Cancer Institute, Carolinas Medical Center, Charlotte, NC, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Forster</LastName>                    <ForeName>Meghan R</ForeName>                    <Initials>MR</Initials>                    <AffiliationInfo>                        <Affiliation>Division of Surgical Oncology, Department of Surgery, Levine Cancer Institute, Carolinas Medical Center, Charlotte, NC, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Warren</LastName>                    <ForeName>Yancey E</ForeName>                    <Initials>YE</Initials>                    <AffiliationInfo>                        <Affiliation>Division of Surgical Oncology, Department of Surgery, Levine Cancer Institute, Carolinas Medical Center, Charlotte, NC, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Livasy</LastName>                    <ForeName>Chad A</ForeName>                    <Initials>CA</Initials>                    <AffiliationInfo>                        <Affiliation>Charlotte Pathology Group, Charlotte, NC, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Sobel</LastName>                    <ForeName>Amy H</ForeName>                    <Initials>AH</Initials>                    <AffiliationInfo>                        <Affiliation>Charlotte Radiology, Charlotte, NC, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Beasley</LastName>                    <ForeName>Lakesha M</ForeName>                    <Initials>LM</Initials>                    <AffiliationInfo>                        <Affiliation>Division of Surgical Oncology, Department of Surgery, Levine Cancer Institute, Carolinas Medical Center, Charlotte, NC, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Trufan</LastName>                    <ForeName>Sally J</ForeName>                    <Initials>SJ</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Cancer Biostatistics, Levine Cancer Institute, Charlotte, NC, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Hadzikadic-Gusic</LastName>                    <ForeName>Lejla</ForeName>                    <Initials>L</Initials>                    <AffiliationInfo>                        <Affiliation>Division of Surgical Oncology, Department of Surgery, Levine Cancer Institute, Carolinas Medical Center, Charlotte, NC, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Sarantou</LastName>                    <ForeName>Terry</ForeName>                    <Initials>T</Initials>                    <AffiliationInfo>                        <Affiliation>Division of Surgical Oncology, Department of Surgery, Levine Cancer Institute, Carolinas Medical Center, Charlotte, NC, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Voci</LastName>                    <ForeName>Amy E</ForeName>                    <Initials>AE</Initials>                    <AffiliationInfo>                        <Affiliation>Division of Surgical Oncology, Department of Surgery, Levine Cancer Institute, Carolinas Medical Center, Charlotte, NC, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Sarma</LastName>                    <ForeName>Deba</ForeName>                    <Initials>D</Initials>                    <AffiliationInfo>                        <Affiliation>Division of Surgical Oncology, Department of Surgery, Levine Cancer Institute, Carolinas Medical Center, Charlotte, NC, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>White</LastName>                    <ForeName>Richard L</ForeName>                    <Initials>RL</Initials>                    <Suffix>Jr</Suffix>                    <AffiliationInfo>                        <Affiliation>Division of Surgical Oncology, Department of Surgery, Levine Cancer Institute, Carolinas Medical Center, Charlotte, NC, USA. richard.white@atriumhealth.org.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Division of Surgical Oncology, Department of Surgery, Levine Cancer Institute, Carolinas Medical Center, 1021 Morehead Medical Drive Suite 6200, Charlotte, NC, 28204, USA. richard.white@atriumhealth.org.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>                <PublicationType UI="D016454">Review</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>09</Month>                <Day>21</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>Netherlands</Country>            <MedlineTA>Breast Cancer Res Treat</MedlineTA>            <NlmUniqueID>8111104</NlmUniqueID>            <ISSNLinking>0167-6806</ISSNLinking>        </MedlineJournalInfo>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">Breast cancer</Keyword>            <Keyword MajorTopicYN="N">Core biopsy</Keyword>            <Keyword MajorTopicYN="N">Digital breast tomosynthesis</Keyword>            <Keyword MajorTopicYN="N">Excisional biopsy</Keyword>            <Keyword MajorTopicYN="N">Radial scar</Keyword>            <Keyword MajorTopicYN="N">Upgrade</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2018</Year>                <Month>07</Month>                <Day>31</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>09</Month>                <Day>15</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>9</Month>                <Day>23</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>9</Month>                <Day>23</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>9</Month>                <Day>23</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>aheadofprint</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30242581</ArticleId>            <ArticleId IdType="doi">10.1007/s10549-018-4973-x</ArticleId>            <ArticleId IdType="pii">10.1007/s10549-018-4973-x</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>